The UK's medical cannabis sector is an interesting one, because it sits at the intersection between pharmaceutical medicine and agricultural product. While cannabis has long been measured in grams and ounces, the modern medical market requires highly precise pharmacological measurements for a regulated and licensed medicine.
First things first, the market is large and growing. There are currently some 80,000 to 90,000 active medical cannabis patients across the UK, and the total sector is worth some ยฃ230 million a year based on the best available estimates. The opportunity for growers and suppliers is a big one because the National Health Service has so far not prescribed cannabis in any significant numbers at all, so the vast majority of prescriptions go through licensed private clinics.
However, the market does not come without its risks. Domestic supply has been limited, growth has been steady but hardly explosive, and overheads are expensive in the sector. There is clear opportunity here. However competitors looking to dominate the space need to do more than grow the highest volumes. Medical cannabis clinics have to balance commercial efficiency, medical responsibility and government regulation while delivering products that fit patients' needs.
Patients Prefer Flower, Making Cost Per Gram Important
The UK has been a global-scale supplier of medical cannabis for pharmaceuticals for many years, but it has struggled to translate that to flower supplied directly to UK patients.
A top cannabis clinic will have tens of thousands of patients and employ hundreds of qualified staff for prescription, delivery and follow-up care. It's services will all be available online, with 80% of UK cannabis prescriptions in 2026 filed through telehealth platforms.
Despite the wide availability of oils, vape cartridges and gummies, flower is the prescription of choice for the vast majority of UK patients as of 2026.
Therefore, the ultimate calculation for suppliers is the cost per saleable gram. In 2026 a gram of medical cannabis flower costs the UK patient ยฃ6.67. This has been rising from around ยฃ5.92 in 2022 - but has remained on par with black market prices for recreational cannabis, if not slightly cheaper. Which is some feat considering all the extra costs involved in licensing and medical-grade production.
On the other hand patients also pay for clinic and consultation fees, delivery costs and additional equipment needed such as a vaporiser. The average British medical cannabis patient spends around ยฃ150 to ยฃ300 a month on their medication, covering clinical costs, product and delivery.
Domestic Supply Still Trails Imports Despite Improvements
Commercial and regulatory factors have meant for years the overwhelming majority of medical cannabis prescribed in the UK has been imported. Mainly from Canada or Germany. Up to 60% from Canada in 2025.
The situation is changing, given that the UK has been for several decades now one of the largest medical cannabis growers in the world. The bulk of that supply was meant for cannabis-based pharmaceutical medicines like Sativex, for which demand has been falling off since more countries have legalised medical flower.
To add to the problem, that kind of cannabis is not licensed for direct medical consumption either. So for a long time the UK had some of the largest stockpiles of medical cannabis globally - but not enough demand. Production infrastructure and expertise is slowly shifting towards domestic medical supply, increasing volume considerably. However, imported supply has grown even faster.
Domestic direct-to-patient medical cannabis supply in the UK also faces significant upfront costs. Licensed medical cannabis grows need to have the highest standards of safety, security and distribution networks compliant with all government standards.
After the product is grown, the situation gets more complicated. UK cultivators need a different licence to convert grown cannabis from Schedule 1 raw material into a finished Schedule 2 medicinal product - and currently no supplier has managed to acquire both licences. This means the process is split between growers and processors, further increasing costs across the business.
Nevertheless, the UK still produces some 15 tonnes of medical cannabis yearly for direct patient supply. That's compared to the 30 tonnes imported in 2026.
On the other hand, in 2020 the UK exported 135 tonnes of medical cannabis for pharmaceutical production. That is around 75% of the global market total.
Administration, Dosage and the Individual Patient
For patients, the world of cultivation licences, ounces, grams and tonnes of imports or global markets is not particularly relevant on a day-to-day basis for their treatment. The price may fluctuate, but the average per gram price peak and low point of the last three years have only diverged by 13% or around ยฃ1 - which won't hit most budgets too hard.
A more important consideration might be the particular cannabis clinic patients choose. In recent years the number of options has increased from around 20 in 2024 to more than 50 licensed clinics as of 2026. This has given rise to a number of comparative online resources, review sites and guides. Prospective patients can look at the different clinics side-by-side across various factors from treatment selection to care quality ratings to the average prices.
One trend that patients might literally feel the effects of is the growing availability of high potency flower. Over the years since medical legalisation in 2018, the average strength of THC (the main psychoactive compound) in cannabis flower prescribed in the UK has risen considerably. In fact, it has done so at a faster rate than the price.
Patients now pay less per milligram of THC than they did in past years, as the potency of flower does not scale with the price rises. In 2022, flower with more than 28% THC was basically zero percent of the UK market. Today it accounts for more than 25% of prescriptions.
Which is not to say that high THC is necessarily better as a clinical choice. In fact, many clinics will recommend patients start out with low THC oils or even balanced CBD and THC products. Various studies have suggested that higher THC levels in medical cannabis can make it a more effective painkiller, but may also come with more of the common side effects like sedation and dizziness.
However, the state of the UK market as it is - based on private clinics instead of NHS GP prescriptions - gives patients more choice as to their own treatment, and they are increasingly opting for higher THC options. Patients should consult with a licensed and regulated clinic on this front, who will be happy to talk through the choices in more detail.